SPRY (ARS Pharmaceuticals) FCF Margin %: -198.17% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SPRY ARS Pharmaceuticals Inc SPRY
28 GF Score
Price $6.06
! 5 Warning Signs
View Full Analysis

What is ARS Pharmaceuticals FCF Margin %?

ARS Pharmaceuticals SPRY +1.51% 28 FCF Margin % is -198.17% as of Mar. 2026. GuruFocus rates SPRY with a GF Score™ of 28/100. The stock has 5 warning signs investors should review. Among 954 Biotechnology companies, ARS Pharmaceuticals ranks worse than 59.96% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. ARS Pharmaceuticals's Free Cash Flow for the three months ended in Mar. 2026 was $-44.95 Mil. ARS Pharmaceuticals's Revenue for the three months ended in Mar. 2026 was $22.68 Mil. Therefore, ARS Pharmaceuticals's FCF Margin % for the quarter that ended in Mar. 2026 was -198.17%.

As of today, ARS Pharmaceuticals's current FCF Yield % is -29.18%.

The historical rank and industry rank for ARS Pharmaceuticals's FCF Margin % or its related term are showing as below:

SPRY' s FCF Margin % Range Over the Past 10 Years
Min: -198136.67   Med: -261.54   Max: 50.86
Current: -177.11

During the past 6 years, the highest FCF Margin % of ARS Pharmaceuticals was 50.86%. The lowest was -198136.67%. And the median was -261.54%.

SPRY's FCF Margin % is ranked worse than
59.96% of 954 companies
in the Biotechnology industry
Industry Median: -77.885 vs SPRY: -177.11

ARS Pharmaceuticals FCF Margin % Related Terms

ARS Pharmaceuticals FCF Margin % Historical Data

* Premium members only.

The historical data trend for ARS Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ARS Pharmaceuticals FCF Margin % Chart

ARS Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial -319.94 -3,060.56 -198,136.67 14.57 -203.14

ARS Pharmaceuticals Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -512.14 -252.23 -145.36 -154.82 -198.17

SPRY vs ALLO, CBIO, IMMX: FCF Margin % Comparison

For the Biotechnology subindustry, ARS Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ARS Pharmaceuticals FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ARS Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where ARS Pharmaceuticals's FCF Margin % falls into.


SPRY
28GF Score
ARS Pharmaceuticals Inc SPRY
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ARS Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

ARS Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-171.205/84.278
=-203.14 %

ARS Pharmaceuticals's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-44.946/22.681
=-198.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -198.17% mean?
ARS Pharmaceuticals (SPRY) has a FCF Margin % of -198.17% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on ARS Pharmaceuticals and its competitors. According to the industry distribution chart, ARS Pharmaceuticals ranks #572 out of 954 companies in the Biotechnology industry, placing it in the top 60%.
Is ARS Pharmaceuticals' FCF Margin % too high?
ARS Pharmaceuticals' current FCF Margin % is -198.17%. Based on the distribution chart, ARS Pharmaceuticals ranks #572 out of 954 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ARS Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does ARS Pharmaceuticals' FCF Margin % compare to ALLO and CBIO?
According to the Biotechnology industry distribution chart, ARS Pharmaceuticals ranks #572 out of 954 companies for FCF Margin %. This places ARS Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on ARS Pharmaceuticals and its competitors. ARS Pharmaceuticals's current FCF Margin % is -198.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ARS Pharmaceuticals stock overvalued right now?
ARS Pharmaceuticals (SPRY) has a current FCF Margin % of -198.17%. The current FCF Margin % is -198.17%. ARS Pharmaceuticals' overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For ARS Pharmaceuticals (SPRY), the current FCF Margin % is -198.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ARS Pharmaceuticals Business Description

Address 11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
28GF Score

Get the complete analysis for SPRY

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.06
Price